Recombinant DNA-derived leishmania proteins: From the laboratory to the field

Lancet Infectious Diseases

Volumn 5, Issue 2, 2005, Pages 107-114

  Kubar, Joanna ^a   Fragaki, Konstantina ^b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b HÔPITAL MAISON BLANCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GENE B PROTEIN; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 70; HISTONE; HISTONE H1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; KINETOPLASTID MEMBRANE PROTEIN 11; LEISHMANIA VACCINE; PROTEIN LEPP12; PROTEIN LIP; PROTOZOAL PROTEIN; RECOMBINANT ANTIGEN; RECOMBINANT CYSTEINE PROTEINASE; RECOMBINANT DNA; RECOMBINANT ELONGATION INITIATION FACTOR; RECOMBINANT GLUCOSE REGULATED PROTEIN 78; RECOMBINANT HEAT SHOCK PROTEIN 70; RECOMBINANT HISTONE H1; RECOMBINANT HYDROPHILIC ACYLATED SURFACE PROTEIN B1; RECOMBINANT K39 ANTIGEN; RECOMBINANT LACK ANTIGEN; RECOMBINANT PROMASTIGOTE SURFACE ANTIGEN 2; RECOMBINANT PROTEIN A2; RECOMBINANT PROTEIN GP46 M2; RECOMBINANT PROTEIN LCR1; RECOMBINANT PROTEIN PAPLE22; RECOMBINANT STRESS INDUCIBLE 1 PROTEIN; RECOMBINANT THIOL SPECIFIC ANTIOXIDANT PROTEIN; UNCLASSIFIED DRUG;

CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; HEALTH CARE COST; HOST PARASITE INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; LABORATORY; LEISHMANIA; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SERODIAGNOSIS; SKIN LEISHMANIASIS; THERAPY RESISTANCE; TOXICITY; VACCINE PRODUCTION; VISCERAL LEISHMANIASIS;

EID: 12944324796     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70085-2     Document Type: Review

References (90)

1. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development. Lancet Infect Dis. 2:2002;494-501
2. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev. 14:2001;229-243
3. Kubar J, Marty P, Lelièvre A, et al. Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T lymphocytes counts. AIDS. 12:1998;2147-2153
4. Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA. 90:1993;775-779
5. Badaro R, Benson D, Eulalio MC, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. Infect Dis. 173:1996;758-761
6. Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis. 177:1998;1339-1344
7. Medrano FJ, Canavate C, Leal M, Rey C, Lissen E, Alvar J. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg. 59:1998;155-162
8. Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health. 6:2001;108-113
9. Veeken H, Ritmeijer K, Seaman J, Davidson R. Comparison of a rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop Med Int Health. 8:2003;164-167
10. Singh S, Kumari V, Singh N. Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen. Clin Diagn Lab Immunol. 9:2002;568-572
11. Sreenivas G, Ansari NA, Singh R, et al. Diagnosis of visceral leishmaniasis: comparative potential of amastigote antigen, recombinant antigen and PCR. Br J Biomed Sci. 59:2002;218-222
12. Maalej IA, Chenik M, Louzir H, et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am J Trop Med Hyg. 68:2003;312-320
13. Carvalho SF, Lemos EM, Corey R, Dietze R. Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis. Am J Trop Med Hyg. 68:2003;321-324
14. Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol. 102:1999;249-261
15. Alce TM, Gokool S, McGhie D, Stager S, Smith DF. Expression of hydrophilic surface proteins in infective stages of Leishmania donovani. Mol Biochem Parasitol. 102:1999;191-196
16. Suffia I, Ferrua B, Stien X, et al. A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. Infect Immun. 68:2000;630-636
17. Fragaki K, Ferrua B, Moghrabi B, Waldispühl J, Kubar J. A novel Leishmania infantum nuclear phosphoprotein Lepp12 which stimulates IL1-beta synthesis in THP-1 transfectants. BMC Microbiol. 3:2003;7
18. Jimenez-Ruiz A, Boceta C, Bonay P, Requena JM, Alonso C. Cloning, sequencing, and expression of the PSA genes from Leishmania infantum. Eur J Biochem. 251:1998;389-397
19. Boceta C, Alonso C, Jimenez-Ruiz A. Leucine rich repeats are the main epitopes in Leishmania infantum PSA during canine and human visceral leishmaniasis. Parasite Immunol. 22:2000;55-62
20. Webb JR, Kaufmann D, Campos-Neto A, Reed SG. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol. 157:1996;5034-5041
21. Webb JR, Campos-Neto A, Ovendale PJ, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun. 66:1998;3279-3289
22. Charest H, Matlashewski G. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol. 14:1994;2975-2984
23. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G. Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol. 4:1997;530-535
24. Carvalho FA, Charest H, Tavares CA, et al. Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis. 43:2002;289-295
25. Jensen AT, Gasim S, Moller T, et al. Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP. Trans R Soc Trop Med Hyg. 93:1999;157-160
26. Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol. 113:2001;35-43
27. Tolson DL, Jardim A, Schnur LF, et al. The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation. Infect Immun. 62:1994;4893-4899
28. Jensen AT, Gasim S, Ismail A, et al. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol. 48:1998;103-109
29. Ramirez JR, Berberich C, Jaramillo A, Alonso C, Velez IV. Molecular and antigenic characterization of the Leishmania (Viannia) panamensis kinetoplastid membrane protein-11. Mem Inst Oswaldo Cruz. 93:1998;247-254
30. de Carvalho LP, Soto M, Jeronimo S, et al. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect. 5:2003;7-12
31. Skeiky YA, Guderian JA, Benson DR, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med. 181:1995;1527-1537
32. Soto M, Requena JM, Quijada L, Alonso C. Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol. 36:1998;58-63
33. Soto M, Requena JM, Quijada L, et al. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol Lett. 48:1995;209-214
34. Soto M, Requena JM, Quijada L, et al. Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis. Clin Exp Immunol. 106:1996;454-461
35. Soto M, Requena JM, Quijada L, et al. Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin Exp Immunol. 115:1999;342-349
36. Quijada L, Requena JM, Soto M, et al. Mapping of the linear antigenic determinants of the Leishmania infantum hsp70 recognized by leishmaniasis sera. Immunol Lett. 52:1996;73-79
37. Quijada L, Requena JM, Soto M, Alonso C. During canine viscero-cutaneous leishmaniasis the anti-Hsp70 antibodies are specifically elicited by the parasite protein. Parasitology. 112:1996;277-284
38. Larreta R, Soto M, Alonso C, Requena JM. Leishmania infantum: gene cloning of the GRP94 homologue, its expression as recombinant protein, and analysis of antigenicity. Exp Parasitol. 96:2000;108-115
39. Bourreau E, Pascalis H, Prevot G, et al. Increased production of interferon-gamma by Leishmania homologue of the mammalian receptor for activated C kinase-reactive CD4+ T cells among human blood mononuclear cells: an early marker of exposure to Leishmania? Scand J Immunol. 58:2003;201-210
40. Berberich C, Requena JM, Alonso C. Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Exp Parasitol. 85:1997;105-108
41. Carmelo E, Martínez E, Cristina González A, et al. Antigenicity of Leishmania braziliensis histone H1 during cutaneous leishmaniasis: localization of antigenic determinants. Clin Diagn Lab Immunol. 9:2002;808-811
42. Skeiky YA, Benson DR, Elwasila M, Badaro R, Burns JM Jr, Reed SG. Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins. Infect Immun. 62:1994;1643-1651
43. Mendez S, Gurunathan S, Kamhawi S, et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol. 166:2001;5122-5128
44. Campos-Neto A, Porrozzi R, Greeson K, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun. 69:2001;4103-4108
45. Coler RN, Skeiky YA, Bernards K, et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun. 70:2002;4215-4225
46. Skeiky YA, Kennedy M, Kaufman D, et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol. 161:1998;6171-6179
47. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun. 63:1995;4261-4267
48. Sjolander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine. 16:1998;2077-2084
49. Noormohammadi AH, Hochrein H, Curtis JM, Baldwin TM, Handman E. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen. Vaccine. 19:2001;4043-4052
50. Mougneau E, Altare F, Wakil AE, et al. Expression cloning of a protective Leishmania antigen. Science. 268:1995;563-566
51. Gurunathan S, Sacks DL, Brown DR, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 186:1997;1137-1147
52. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med. 4:1998;1409-1415
53. Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun. 56:1988;3272-3279
54. Jensen AT, Curtis J, Montgomery J, Handman E, Theander TG. Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani(1). Biochim Biophys Acta. 1549:2001;73-87
55. Solioz N, Blum-Tirouvanziam U, Jacquet R, et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 18:1999;850-859
56. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19:2001;3369-3375
57. Mottram JC, Brooks DR, Coombs GH. Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Curr Opin Microbiol. 1:1998;455-460
58. Wilson ME, Young BM, Andersen KP, et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun. 63:1995;2062-2069
59. Streit JA, Recker TJ, Donelson JE, Wilson ME. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol. 94:2000;33-41
60. Ghosh A, Zhang WW, Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine. 20:2001;59-66
61. Ghosh A, Labrecque S, Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine. 19:2001;3169-3178
62. Stager S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol. 165:2000;7064-7071
63. Fragaki K, Suffia I, Ferrua B, Rousseau D, Le Fichoux Y, Kubar J. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine. 19:2001;1701-1709
64. Ramiro MJ, Zarate JJ, Hanke T, et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine. 21:2003;2474-2484
65. Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun. 70:2002;2828-2836
66. Probst P, Skeiky YA, Steeves M, Gervassi A, Grabstein KH, Reed SG. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol. 27:1997;2634-2642
67. McSorley SJ, Rask C, Pichot R, Julia V, Czerkinsky C, Glaichenhaus N. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur J Immunol. 28:1998;424-432
68. Gurunathan S, Sacks DL, Brown DR, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 186:1997;1137-1147
69. Okuno T, Takeuchi M, Matsumoto Y, Otsuka H, Matsumoto Y. Pretreatment of leishmania homologue of receptors for activated C kinase (LACK) promotes disease progression caused by Leishmania amazonensis. Exp Anim. 51:2002;335-341
70. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun. 69:2001;4719-4725
71. Coelho EA, Tavares CA, Carvalho FA, et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun. 71:2003;3988-3994
72. Handman E, Button LL, McMaster RW. Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol. 70:1990;427-435
73. Kaye PM, Curry AJ, Blackwell JM. Differential production of Th1 and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol. 146:1991;2763-2770
74. Rousseau D, Le Fichoux Y, Stien X, Suffia I, Ferrua B, Kubar J. Progression of visceral leishmaniasis due to Leishmania infantum in BALB/c mice is markedly slowed down by prior infection with Trichinella spiralis. Infect Immun. 65:1997;4978-4983
75. Wilson ME, Sandor M, Blum AM, et al. Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J Immunol. 156:1996;2231-2239
76. Le Fichoux Y, Rousseau D, Ferrua B, et al. Short and long term efficacy of hexadecylphosphocholine in established Leishmania infantum infection of BALB/c mice. Antimicrob Agents Chemother. 42:1998;654-658
77. Rousseau D, Demartino S, Anjuère F, et al. Sustained parasite burden in spleen of Leishmania infantum infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection against rechallenge. Eur Cytokine Netw. 12:2001;340-347
78. Skeiky YA, Benson DR, Guderian JA, et al. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun. 63:1995;4105-4114
79. Bourreau E, Prevot G, Gardon J, et al. LACK-specific CD4(+) T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection. Infect Immun. 70:2002;3122-3129
80. Maasho K, Wolday D, Edjigu M, Soderstrom K, Britton S, Akuffo H. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. Clin Exp Immunol. 124:2001;255-261
81. Anjuere F, George-Chandy A, Audant F, Rousseau D, Holmgren J, Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol. 170:2003;1586-1592
82. Fragaki K. Protéines de Leishmania infantum. PapLe22: étude de sa capacité vaccinale. Lepp12: identification et étude de son rôle potentiel dans la dérégulation de la cellule hôte (PhD thesis). University of Nice, France: 2002.
83. Zhang WW, Matlashewski G. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci USA. 94:1997;8807-8811
84. Matlashewski G. Leishmania infection and virulence. Med Microbiol Immunol. 190:2001;37-42
85. Wiese M, Gorcke I. Homologues of LMPK, a mitogen-activated protein kinase from Leishmania mexicana, in different Leishmania species. Med Microbiol Immunol. 190:2001;19-22
86. Wiese M. A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO J. 17:1998;2619-2628
87. Gilbert IH. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim Biophys Acta. 1587:2002;249-257
88. Schmidt A, Krauth-Siegel RL. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr Top Med Chem. 2:2002;1239-1259
89. Cui L, Rajasekariah GR, Martin SK. A nonspecific nucleoside hydrolase from Leishmania donovani: implications for purine salvage by the parasite Gene. 280:2001;153-162
90. Shi W, Schramm VL, Almo SC. Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-Å crystal structure. J Biol Chem. 274:1999;21114-21120